AIM To explore the feasibility and safety of transcatheter closure of perimembranous ventricular septal defects (PmVSD) with abnormally attached tricuspid chordae tendineae using an domestic improved patent ductus arteriosus (PDA) occluder.
METHODS We retrospectively analyzed 35 patients diagnosed as PmVSD with abnormally attached tricuspid chordae tendineae who underwent interventional treatment using an improved PDA occluder at our center from December 2012 to December 2019. Baseline characteristics and procedural and follow-up data were analyzed.
RESULTS All 35 patients (100%) achieved procedure success. No heart block occurred during the operation. One patient (2.9%) had a transient complete right bundle branch block within 48 h post-procedure and reverted to normal rhythm after intravenous injections of dexamethasone for 3 d. No residual shunt was observed in the 35 patients (100%) by transthoracic echocardiography (TTE) post-procedure. During the average follow-up period of (4.4±2.3) years, 1 case (2.9%) had an increase in tricuspid regurgitation (TR) compared with preoperatively, which was a moderate amount of TR. No severe TR or aggravated TR was observed in the remaining patients.
CONCLUSION Improved PDA occluder for the transcatheter closure of PmVSD with abnormally attached tricuspid chordae tendineae is a safe and promising treatment option. However, long-term follow-up in a larger group of patients is still warranted.
DownLoad: